2019
DOI: 10.1007/s00259-019-04485-3
|View full text |Cite
|
Sign up to set email alerts
|

EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

8
273
0
21

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 310 publications
(365 citation statements)
references
References 46 publications
8
273
0
21
Order By: Relevance
“…The visual distinction between parotids and liver miPSMA expression scores is simple for patients 1 and 2 while miPSMA expression scores of liver and parotids is visually similar for patients 3 and 4. Left side of the figure adapted from Eiber et al figure [7] agents [28]. For example, one phase II trial on 177 Lu-PSMA-617 required a baseline [ 68 Ga]Ga-PSMA-11 SUVmax at dominant sites of tumour involvement to be at least 1.5 times the SUV mean of the liver [29].…”
Section: Discussionmentioning
confidence: 99%
“…The visual distinction between parotids and liver miPSMA expression scores is simple for patients 1 and 2 while miPSMA expression scores of liver and parotids is visually similar for patients 3 and 4. Left side of the figure adapted from Eiber et al figure [7] agents [28]. For example, one phase II trial on 177 Lu-PSMA-617 required a baseline [ 68 Ga]Ga-PSMA-11 SUVmax at dominant sites of tumour involvement to be at least 1.5 times the SUV mean of the liver [29].…”
Section: Discussionmentioning
confidence: 99%
“…Patients with castration-resistant prostate cancer (mCRPC) typically present a large metastatic tumor burden in the bones (3). Radioligand therapies (RLT) targeting the prostatespecific membrane antigen (PSMA) such as Lutetium-177-PSMA (Lu-177-PSMA) and Actinium-225-PSMA have shown promising results in patients ineligible for other therapies or showing progress after receiving other systemic treatment options (4). The clinical value of personalized dosimetry in RLT lies in a possible increase of the therapeutic window by limiting absorbed dose to organs at risk (OARs) while maximizing absorbed dose to tumors.…”
Section: Introductionmentioning
confidence: 99%
“…Automated modules are regularly used to ensure consistency of labeling the radionuclide to the target to produce the radiopharmaceutical. The so-called GMP module is utilized for the pharmaceutical labeling of a limited number of radionuclides for clinical diagnosis and therapy, namely, 18 F, 11 C, 15 O, 13 N, 68 Ga, 99m Tc, 90 Y and 177 Lu [85][86][87][88].…”
Section: Automation Of the Labeling Procedures Towards Gmp Productionmentioning
confidence: 99%
“…It is worth mentioning that to bring a novel radionuclide from the development stage to the clinic is a long process. Phase III data for 177 Lu demonstrated that radioactive drugs took more than 15 years to achieve the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) approval [18]. So far, only 177 Lu-DOTATATE has been approved for clinical use, while four other 177 Lu-based radiopharmaceuticals have been clinically tested [19][20][21].…”
Section: Introductionmentioning
confidence: 99%